Bryce Point Capital LLC Buys Shares of 22,709 Capricor Therapeutics Inc (NASDAQ:CAPR)

Bryce Point Capital LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 22,709 shares of the biotechnology company’s stock, valued at approximately $313,000.

Other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 44.4% during the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock worth $31,420,000 after purchasing an additional 700,243 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Capricor Therapeutics by 37.8% during the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock valued at $12,139,000 after purchasing an additional 241,279 shares during the period. State Street Corp raised its stake in shares of Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after buying an additional 111,291 shares in the last quarter. Black Diamond Financial LLC acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at $3,833,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at $3,806,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on CAPR shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Down 2.3 %

NASDAQ CAPR opened at $9.06 on Friday. Capricor Therapeutics Inc has a 1 year low of $3.52 and a 1 year high of $23.40. The company has a market cap of $413.82 million, a PE ratio of -8.55 and a beta of 4.09. The stock’s 50-day moving average price is $13.50 and its two-hundred day moving average price is $15.02.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. The business had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Research analysts forecast that Capricor Therapeutics Inc will post -1.21 EPS for the current fiscal year.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.